Skip to main content
. 2021 Mar 30;204(10):1153–1163. doi: 10.1164/rccm.202009-3539OC

Table 1.

Characteristics of Trial Participants by APACHE-II

Variable Low APACHE-II*
(n = 99)
High APACHE-II*
(n = 101)
Difference (95% CI)
Age 57 (42 to 67) 58 (47 to 67) −2 (–7 to 3)
Sex, F, n (%) 52 (52.5) 40 (39.6) 12.9 (–0.8 to 26.6)
Weight, kg 85.4 (72.0 to 110.3) 77.8 (69.0 to 96.5) 7.6 (1.3 to 14.1)
Body mass index, kg/m2 31.1 (26.4 to 39.7) 28.3 (24.8 to 33.4) 2.7 (0.7 to 4.9)
Time intubated prior to enrollment, h 21.5 (15 to 30) 21 (13 to 33) 0 (–4 to 4)
APACHE-II at enrollment 21 (4) 33 (4) −12 (–14 to –11)
 Acute physiology subscore 18 (4) 30 (4) −12 (–13 to –11)
 Chronic health subscore 3 (2) 3 (2) −1 (–1 to 0)
SOFA at enrollment 8.5 (6 to 10) 13 (12 to 15) −5 (–6 to –4)
ARDS risk factor, n (%)      
 Sepsis 87 (87.9) 84 (83.2) 4.7 (–5.0 to 14.4)
 Pneumonia 78 (78.8) 71 (70.3) 8.5 (–3.5 to 20.5)
 Aspiration 17 (17.2) 25 (24.8) −7.6 (–18.8 to 3.7)
 Multiple transfusions 5 (5.1) 14 (13.9) −8.8 (–16.8 to –0.8)
 Acute pancreatitis 1 (1.0) 6 (5.9) −4.9 (–9.9 to 0.1)
 Trauma 3 (3.0) 3 (3.0) −0.1 (–5.7 to 4.8)
 Any pulmonary risk factor 87 (87.9) 83 (82.2) 5.7 (–4.2 to 15.6)
Respiratory characteristics at enrollment      
 pH 7.36 (7.31 to 7.40) 7.29 (7.23 to 7.35) 0.06 (0.04 to 0.08)
 PaCO2, mm Hg 45 (37 to 52) 43 (37 to 50) 1 (–2 to 4)
 PaO2:FiO2 95 (75 to 132) 86 (69 to 119) 7 (–4 to 16)
 Vt, ml/kg PBW 6.2 (5.9 to 6.8) 6.1 (5.9 to 7.0) 0.1 (–0.1 to 0.3)
 Respiratory rate, breaths/min 25 (22 to 29) 26 (23 to 30) −2 (–3 to 0)
V˙e, L/min 9.4 (8.4 to 11.2) 10.2 (8.5 to 12.2) −0.5 (–1.3 to 0.2)
 Ventilatory ratio 1.9 (1.6 to 2.3) 2.0 (1.6 to 2.3) 0.0 (–0.2 to 0.1)
 Set PEEP, cm H2O 14 (10 to 16) 14 (10 to 16) 0 (–2 to 1)
 Plateau airway pressure, cm H2O 28 (24 to 31) 27 (25 to 31) 0 (–1 to 2)
 Driving airway pressure, cm H2O 13 (10 to 15) 13 (10 to 14) 0 (–1 to 1)
 Pes, cm H2O      
  At end-expiration 16 (12 to 19) 16 (13 to 18) −1 (–2 to 1)
  At end-inspiration 18 (15 to 21) 19 (16 to 21) −1 (–2 to 0)
 Transpulmonary pressure, cm H2O      
  At end-expiration −1 (–4 to 2) −1 (–3 to 1) 0 (–1 to 1)
  At end-inspiration 8 (5 to 12) 8 (5 to 11) 0 (–1 to 2)
Cointerventions at enrollment, n (%)      
 Vasopressors 45 (45.5) 69 (68.3) −22.9 (–36.2 to –9.5)
 Neuromuscular blockade 28 (28.3) 38 (37.6) −9.3 (–22.3 to 3.6)
 Systemic corticosteroids 34 (34.3) 35 (34.7) −0.3 (–13.5 to 12.9)
Treatment assignment, n (%)      
 Pes-guided PEEP 51 (51.5) 51 (50.5) 1.0 (–12.8 to 14.9)
 Empirical PEEP 48 (48.5) 50 (49.5) −1.0 (–14.9 to 12.8)
Outcomes      
 28-d mortality, n (%) 21 (21.2) 42 (41.6) −20.4 (–32.9 to –7.8)
 60-d mortality, n (%) 29/98 (29.6) 46/101 (45.5) −15.9 (–29.2 to –2.7)
 Ventilator-free days through Day 28 20 (0 to 24) 9 (0 to 22) 2 (0 to 6)
 Shock-free days through Day 28 18 (7 to 22) 9 (0 to 20) 4 (1 to 7)

Definition of abbreviations: APACHE-II = Acute Physiology and Chronic Health Evaluation II; ARDS = acute respiratory distress syndrome; CI = confidence interval; PBW = predicted body weight; PEEP = positive end-expiratory pressure; Pes = esophageal pressure; SOFA = sequential organ failure assessment.

Data are shown as median (interquartile range) unless otherwise indicated.

*

Low and high APACHE-II refer to patients with values less or greater than the median APACHE-II score, which was 27.5.

Hodges-Lehmann estimation was used to determine unbiased median differences and 95% CIs for variables reported as median (interquartile range). The result represents the median difference among all possible pairs formed by one patient from each group and thus does not necessarily equal the crude difference between group medians.

Ventilatory ratio is a surrogate for dead-space fraction calculated as [V˙e (ml/min) × PaCO2 (mm Hg)]/(predicted body weight × 100 × 37.5).